- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
February 28, 2022
PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner.
February 25, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
February 25, 2022
Robotic partial nephrectomy in 3D virtual reconstructions era: is the paradigm changed?
February 24, 2022
Exploration of Prognostic Immune-Related Genes and lncRNAs Biomarkers in Kidney Renal Clear Cell Carcinoma and Its Crosstalk with Acute Kidney Injury.
February 24, 2022
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
February 23, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
February 23, 2022
Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.
February 22, 2022
The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
February 21, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
February 21, 2022
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
February 21, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
February 18, 2022
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
February 18, 2022
Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona.
February 17, 2022
The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions.
February 17, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
February 17, 2022